secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABBOTT LABORATORIES (ABT)
CIK:        0000001800
Form:       8-K
Filed at:   2024-04-17T23:59:59+00:00
Accession:  0001628280-24-016497
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abbott Q1 adj. EPS $0.98; raises FY2024 midpoint guidance
---------------------------------------------------------

- Q1 GAAP diluted EPS $0.70; adjusted diluted EPS $0.98; revenue $9.96B (+2.2% reported).
- Organic base business sales grew 10.8% YoY; fifth consecutive double-digit quarter.
- FY2024 adjusted EPS guidance raised to $4.55-$4.70 midpoint; organic sales growth 8.5%-10.0% ex-COVID tests.
- Medical Devices organic sales +14.3%; FreeStyle Libre revenue $1.5B (+22.4% reported).
- FDA approved TriClip for tricuspid regurgitation and i-STAT TBI test; quarterly dividend $0.55/share maintained.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800/000162828024016497/0001628280-24-016497-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800/000162828024016497/abt-20240417.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-016497

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer